Restatement of Previously Issued Financial Statements - Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jul. 31, 2023	Jul. 22, 2023	Jul. 21, 2023	Jun. 30, 2023	Jan. 01, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Jan. 01, 2022
Restatement of Previously Issued Financial Statements
Contingent consideration liability	$ 81,161
Assumed liabilities	146,015						$ 143,242
Additional paid-in capital	379,669						187,348
Accumulated deficit	(447,359)						(474,839)
Total AEON Biopharma, Inc. stockholders' deficit	(128,396)						(287,500)
Total stockholders' deficit	(128,396)	$ (310,820)	$ (180,856)	$ (310,820)	$ (283,889)	$ (270,413)	$ (270,413)	$ (237,593)	$ (228,228)	$ (223,824)
As Reported
Restatement of Previously Issued Financial Statements
Contingent consideration liability	74,505
Assumed liabilities	139,359
Additional paid-in capital	362,114
Accumulated deficit	(423,148)
Total AEON Biopharma, Inc. stockholders' deficit	(121,740)
Total stockholders' deficit	(121,740)		(167,976)	(288,159)
Adjustment
Restatement of Previously Issued Financial Statements
Contingent consideration liability	6,656
Assumed liabilities	6,656
Additional paid-in capital	17,555
Accumulated deficit	(24,211)
Total AEON Biopharma, Inc. stockholders' deficit	(6,656)
Total stockholders' deficit	$ (6,656)		$ (12,880)	$ (22,661)